Anti-aging rapamycin and metformin in Panama: evidence and law

Why patients ask about rapamycin and metformin in Panama

In Panama, as elsewhere, physicians hear the same request more often: «I want a longevity protocol with rapamycin or metformin». Both are old generic drugs. Rapamycin (sirolimus) is an mTOR inhibitor used in kidney transplantation; metformin is first-line treatment for type 2 diabetes. Neither was developed to «slow aging», and the clinical question is what we really know in healthy people¹¹⁰.

This article is journalism and an evidence review for physicians. It does not recommend or describe use regimens in people.

Rapamycin: promise in mice, limited human evidence

The case in favor starts in animals. In a 2009 study in Nature, genetically heterogeneous mice given rapamycin from 600 days of age lived longer: by age at 90% mortality, the increase was 14% in females and 9% in males⁴.

In healthy humans the picture is more modest. The review by Hands, Lustgarten, Frame and Rosen, published in Aging on August 7, 2025, examines the evidence for low-dose rapamycin and its analogues and concludes that human data have yet to establish it as a proven «seno-therapeutic» able to delay aging in healthy older adults². According to the George Washington University press release, first author Jacob Hands put it this way: «We simply don’t have enough evidence to recommend its use as a longevity therapy at this time»¹.

The PEARL trial (Aging, 2025) was randomized, double-blind and placebo-controlled for 48 weeks, using compounded rapamycin 5 mg or 10 mg weekly. Visceral fat, the primary outcome, did not change significantly; adverse events were similar across groups, and improvements in lean mass and pain appeared in women on 10 mg, and in emotional well-being and general health on 5 mg³. The authors disclose that they are employees and shareholders of AgelessRx, the company that offers the service, and the work is described as a safety study³.

An earlier 6-week phase 2a trial in 264 older adults tested a combination of a catalytic (BEZ235) and an allosteric (RAD001) mTOR inhibitor, not rapamycin. It reported a significant drop in infections over the following year and a better influenza vaccine response⁵. It is an interesting immune signal, but it is not evidence that rapamycin extends life.

What is known about the risks

The most solid safety data come from transplantation, a very different setting. A 2013 meta-analysis in kidney transplantation (11,432 participants in 48 articles) linked sirolimus with higher risk of anemia, diabetes, dyslipidemia and lymphoceles compared with tacrolimus or cyclosporine¹². Those figures cannot be extrapolated to low intermittent doses in healthy people, but they are a reminder that it is an immunosuppressant with metabolic effects. A 2019 KFF Health News report already noted that there is little evidence healthy people would benefit and that little is known about side effects in the general population, including the possibility of insulin resistance¹⁵.

Metformin: solid in diabetes, weak as a geroprotector

Metformin activates AMPK, inhibits mTOR and alters pathways tied to aging, which is why it is considered a candidate geroprotective agent¹⁰. The Targeting Aging with Metformin (TAME) trial was designed to test whether it delays several age-related diseases⁹. A review published in Aging in August 2026 describes it as a landmark trial that could shift the clinical approach to aging and calls for more studies¹⁰. As far as we could verify, no TAME results have been published.

Meanwhile, a randomized trial in healthy adults aged 65 or older (MASTERS) found that with 1,700 mg/day of metformin during 14 weeks of strength training, the placebo group gained more lean mass (p = 0.003) and more thigh muscle mass (p < 0.001) than the metformin group⁶. A muscle-transcriptome analysis of those participants looked for the mechanism⁷, and a 2026 review calls it a «therapeutic paradox»: possible protection in frail or insulin-resistant people, and a limit on anabolic adaptation in active older adults⁸.

One more practical point: a systematic review of 19 studies in type 2 diabetes found a correlation between metformin and vitamin B12 deficiency, with higher risk at higher doses, and recommends measuring B12 during long treatment¹¹. That finding is in diabetic patients, not healthy people.

Which legal framework applies in Panama

Ley 419 of February 1, 2024 regulates medicines in Panama, and Executive Decree 27 of May 10, 2024, which implements it, took effect on publication in the Gaceta Oficial¹⁴. Article 4 establishes that every product regulated by the law must be registered with the National Directorate of Pharmacy and Drugs (DNFD)¹³. The same law defines an over-the-counter medicine as one whose sale does not require a medical prescription (art. 3, item 57) and a prescription as one issued by a qualified physician (art. 3, item 71)¹³.

In the text we reviewed we found no specific provision on off-label use of these drugs, although the document is long and we could not read all of it¹³. In practice, the authorized indication is set by each product's sanitary registration, and prescribing rapamycin or metformin for longevity is a clinical decision outside that indication, with the physician's responsibility. We also found no published Ministry of Health (MINSA) alerts on these two drugs in longevity clinics. For general context see our analysis of longevity clinics in Panama and the peptide guide for Panama.

What a physician can tell the patient who asks

• Neither drug has human evidence showing extended lifespan or healthspan in healthy adults²¹⁰.
• Rapamycin is an immunosuppressant; its known risks come mainly from transplantation, and the data in healthy people are a few short trials³¹².
• Metformin has clear benefits in type 2 diabetes and a possible cost in older adults who strength train⁶¹⁰.
• If the patient insists, document that the use is off-label and that TAME results are not published⁹¹⁰.